pantoprazole+bismuth+tetra+metro

PreclinicalSmall molecule

pantoprazole+bismuth+tetra+metro is one of 6 small molecule programs targeting Bismuth Quadruple Therapy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bismuth Quadruple TherapyCompleted

Bismuth Quadruple TherapyPreclinical

Completed

Competition

Competitive Landscape

5 competitors in Bismuth Quadruple Therapy

#DrugCompanyPhaseTrials

Nexium

DDexcel Pharma Technologies Ltd.

Approved

3 2

Achromycin V

WWyeth-Lederle Vaccines

Approved

1 3

Furoxone

UUniversity of New Hampshire

Approved

1 4

Bismuth

SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.

Phase 3

2 5

Saccharomyces Boulardii

BBiocodex

Phase 3

1 6

pantoprazole+bismuth+tetra+metro

KKaohsiung Veterans General Hospital.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bismuth Quadruple Therapy1 trial

Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy

Completed·KKaohsiung Veterans General Hospital.·N/A·NCT02547038·352 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for pantoprazole+bismuth+tetra+metro. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pantoprazole+bismuth+tetra+metro compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pantoprazole+bismuth+tetra+metro. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kaohsiung Veterans General Hospital. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKaohsiung Veterans General Hospital.

pantoprazole+bismuth+tetra+metro

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bismuth Quadruple Therapy1 trial

References

Drug Info

Quick Facts

Related News